Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.

West J, Robertson-Tessi M, Luddy K, Park DS, Williamson DFK, Harmon C, Khong HT, Brown J, Anderson ARA.

JCO Clin Cancer Inform. 2019 Feb;(3):1-12. doi: 10.1200/CCI.18.00078.

2.

Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.

Khong B, Lawson BO, Ma J, McGovern C, Van Atta JK, Ray A, Khong HT.

BMC Cancer. 2018 Oct 20;18(1):1007. doi: 10.1186/s12885-018-4810-y.

3.

Neutrophil-to-lymphocyte Ratio (NLR) as a predictor for recurrence in patients with stage III melanoma.

Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, Hahn AW, Khong HT.

Sci Rep. 2018 Mar 6;8(1):4044. doi: 10.1038/s41598-018-22425-3.

4.

A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors.

Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL, Butler TW, Dumlao T, Khong HT.

Oncotarget. 2016 Dec 26;8(32):52413-52419. doi: 10.18632/oncotarget.14183. eCollection 2017 Aug 8.

5.

A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer.

Werner TL, Ray A, Lamb JG, VanBrocklin M, Hueftle K, Cohen AL, Beck AC, Buys SS, Dyess DL, Butler TW, Dumlao TL, Neumayer L, Khong HT.

Clin Breast Cancer. 2017 Nov;17(7):503-509. doi: 10.1016/j.clbc.2017.04.010. Epub 2017 Apr 29.

PMID:
28579139
6.

Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis.

Bowen RC, Little NAB, Harmer JR, Ma J, Mirabelli LG, Roller KD, Breivik AM, Signor E, Miller AB, Khong HT.

Oncotarget. 2017 May 9;8(19):32171-32189. doi: 10.18632/oncotarget.16291. Review.

7.
8.

Complete response to azacitidine priming and nab-paclitaxel in non-Hodgkin lymphoma resistant to biochemotherapy.

Bowen RC, Hahn AW, Butler TW, Khong HT.

Mol Clin Oncol. 2017 Jan;6(1):122-124. doi: 10.3892/mco.2016.1090. Epub 2016 Nov 23.

9.

A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer.

Ray A, Khong B, Khong HT.

Anticancer Res. 2016 Dec;36(12):6673-6676.

PMID:
27920001
10.

miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20.

Liu Z, Smith KR, Khong HT, Huang J, Ahn EE, Zhou M, Tan M.

Oncotarget. 2016 Nov 29;7(48):78667-78679. doi: 10.18632/oncotarget.12018.

11.

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.

Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT.

Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453.

12.

miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance.

Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O, Tan M.

J Biol Chem. 2013 Feb 8;288(6):4334-45. doi: 10.1074/jbc.M112.419168. Epub 2012 Dec 19.

13.

Demethylating Agents in the Treatment of Cancer.

Howell PM, Liu Z, Khong HT.

Pharmaceuticals (Basel). 2010 Jul 2;3(7):2022-2044. Review.

14.

Activated CD4+ T cells enhance radiation effect through the cooperation of interferon-gamma and TNF-alpha.

Wang Y, Radfar S, Khong HT.

BMC Cancer. 2010 Feb 23;10:60. doi: 10.1186/1471-2407-10-60.

15.
16.

Activated CD4+ T cells dramatically enhance chemotherapeutic tumor responses in vitro and in vivo.

Radfar S, Wang Y, Khong HT.

J Immunol. 2009 Nov 15;183(10):6800-7. doi: 10.4049/jimmunol.0901747. Epub 2009 Oct 21.

17.

Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth.

Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M.

Oncogene. 2009 Oct 22;28(42):3689-701. doi: 10.1038/onc.2009.229. Epub 2009 Aug 10.

PMID:
19668225
18.

Immunotherapy of melanoma: a critical review of current concepts and future strategies.

Riker AI, Radfar S, Liu S, Wang Y, Khong HT.

Expert Opin Biol Ther. 2007 Mar;7(3):345-58. Review.

PMID:
17309326
19.

Transduction of an HLA-DP4-restricted NY-ESO-1-specific TCR into primary human CD4+ lymphocytes.

Zhao Y, Zheng Z, Khong HT, Rosenberg SA, Morgan RA.

J Immunother. 2006 Jul-Aug;29(4):398-406.

20.

Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor.

Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC.

J Immunother. 2005 Nov-Dec;28(6):551-9.

PMID:
16224272
21.

Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy.

Liu G, Akasaki Y, Khong HT, Wheeler CJ, Das A, Black KL, Yu JS.

Oncogene. 2005 Aug 4;24(33):5226-34.

PMID:
15897911
22.

Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Huang J, Khong HT, Dudley ME, El-Gamil M, Li YF, Rosenberg SA, Robbins PF.

J Immunother. 2005 May-Jun;28(3):258-67.

23.

Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines.

Zhao Y, Zheng Z, Robbins PF, Khong HT, Rosenberg SA, Morgan RA.

J Immunol. 2005 Apr 1;174(7):4415-23.

24.

Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.

Klebanoff CA, Khong HT, Antony PA, Palmer DC, Restifo NP.

Trends Immunol. 2005 Feb;26(2):111-7. Review. No abstract available. Erratum in: Trends Immunol. 2005 Jun;26(6):298.

25.

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.

Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA.

J Immunother. 2004 Nov-Dec;27(6):472-7.

27.

Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma.

Liu G, Khong HT, Wheeler CJ, Yu JS, Black KL, Ying H.

J Immunother. 2003 Jul-Aug;26(4):301-12.

PMID:
12843792
28.

Natural selection of tumor variants in the generation of "tumor escape" phenotypes.

Khong HT, Restifo NP.

Nat Immunol. 2002 Nov;3(11):999-1005. Review.

32.

Chlorambucil-induced pulmonary disease: a case report and review of the literature.

Khong HT, McCarthy J.

Ann Hematol. 1998 Jul-Aug;77(1-2):85-7. Review.

PMID:
9760160

Supplemental Content

Loading ...
Support Center